Followers | 751 |
Posts | 16574 |
Boards Moderated | 0 |
Alias Born | 05/30/2007 |
Friday, December 01, 2023 12:48:40 PM
Nuwellis, Inc.
Tue, November 28, 2023 at 2:00 PM GMT+1
Recommendation Rating: Buy
Nuwellis, Inc.
The data demonstrate that the hematocrit sensor within the Nuwellis Aquadex® system offers unique advantages for fluid overloaded small patients
MINNEAPOLIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- New real-world data demonstrate that pediatric patients with fluid overload respond well to Aquadex® ultrafiltration therapy with continuous hematocrit monitoring, announced Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload. The publication, “Using Aquapheresis with Continuous Hematocrit Monitoring to Guide Ultrafiltration,” was featured in Pediatric Nephrology. 1
The publication is a single-center case study review of pediatric patients with hypoalbuminemia and severe fluid overload. Patients were treated with Nuwellis’ Aquadex® ultrafiltration therapy with continuous hematocrit monitoring to guide isotonic fluid removal. The study concluded that the therapy successfully treated small patients without hemodynamic instability or other complications, demonstrating that Aquadex is an effective treatment option for fluid overload.
“We’re proud to share new evidence supporting the clinical need and applications for Aquadex among pediatric patients, and we’re grateful to Dr. Michelle Starr and her colleagues for their trust and confidence in our therapy,” said Nestor Jaramillo, Jr., President and Chief Executive Officer of Nuwellis. “Our proprietary hematocrit sensor which is incorporated into the Aquadex console was a result of physician feedback and observations from clinical studies that drove us to make our Aquadex therapy even smarter. Our team is committed to supporting diuretic-resistant patients broadly, and I’m encouraged to see data validating this strategy as Nuwellis works to expand access to ultrafiltration to even more patients and clinicians.”
“Managing fluid overload for pediatric patients can be challenging, but these new data and our growing library of evidence support our view that Aquadex can provide a safe and effective method for restoring fluid balance,” said John Jefferies, MD, Chief Medical Officer of Nuwellis. “The continuous hematocrit monitoring function within the Aquadex provides unique and proprietary therapeutic direction, as demonstrated in this important publication.”
Effectively managing fluid overload for pediatric patients is critical. Fluid overload is associated with significant increases in mortality in pediatric patients. Research has shown that a 3% increase in mortality is observed for every 1% increase in fluid overload among these patients. 2,3
Aquadex is proven to simply, safely, and precisely remove excess fluid from patients suffering from fluid overload who have not responded to conventional medical management, including diuretics. Providers can specify and adjust the rate of fluid removed for each individual patient, resulting in a gradual reduction of excess fluid. The device’s built-in, customizable hematocrit monitoring technology provides real-time measurement of percent blood volume changes that can be tailored to individual patients’ needs. A customizable fluid removal rate is particularly important for pediatric patients, who have a small amount of blood in their bodies. The Aquadex system is cleared by the FDA for use in adults and pediatric patients weighing 20 kg (44 lbs.) or more.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or Twitter.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
CONTACTS:
Investors:
Vivian Cervantes
Gilmartin Group
ir@nuwellis.com
Media:
Laurel Hood
Health+Commerce
laurel@healthandcommerce.com
Link: https://finance.yahoo.com/news/real-world-data-highlight-clinical-130000845.html
$$$NUWE$$$
Recent NUWE News
- Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy • GlobeNewswire Inc. • 05/09/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 09:28:54 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 05/08/2024 09:26:11 PM
- Nuwellis, Inc. Announces First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 12:00:00 PM
- Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology • GlobeNewswire Inc. • 05/02/2024 01:00:00 PM
- Nuwellis Announces Closing of $2.7 Million Public Offering • GlobeNewswire Inc. • 04/30/2024 10:09:12 PM
- Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 04/30/2024 08:41:07 PM
- Nuwellis Announces Pricing of $2.7 Million Public Offering • GlobeNewswire Inc. • 04/26/2024 01:17:51 PM
- Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health • GlobeNewswire Inc. • 04/09/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 09:08:24 PM
- Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 03/07/2024 02:08:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 05:02:05 PM
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/05/2024 01:00:00 PM
- U.S. Futures Dip, Crude Oil Fluctuates • IH Market News • 03/05/2024 11:05:54 AM
- Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 • GlobeNewswire Inc. • 02/27/2024 02:00:00 PM
- Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™ • GlobeNewswire Inc. • 02/22/2024 12:58:00 PM
- Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/20/2024 10:06:53 PM
- Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 02/20/2024 01:42:52 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/08/2024 10:19:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:07:29 PM
- New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/09/2024 10:30:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 02:24:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:25:39 PM
- Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter • GlobeNewswire Inc. • 01/04/2024 08:05:13 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM